NCT02988440View on ClinicalTrials.gov

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 20, 2017

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

PDR001

PDR001 will be administered intravenously

DRUG

Sorafenib

Sorafenib is formulated as a tablet.

Trial Locations (9)

10002

Novartis Investigative Site, Taipei

20089

Novartis Investigative Site, Rozzano

31008

Novartis Investigative Site, Pamplona

45147

Novartis Investigative Site, Essen

48201

Karmanos Cancer Institute, Detroit

H3T 1E2

Novartis Investigative Site, Montreal

Unknown

Novartis Investigative Site, Hong Kong

277 8577

Novartis Investigative Site, Kashiwa

232 0024

Novartis Investigative Site, Yokohama

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY